Hypomethylating Agents Use in Acute Myeloid Leukemia: A Single-Center Experience.

Bodepudi, Sravan Kumar; Devdas, Santhosh Kumar; Maka, Vinayak V.; Palassery, Rasmi; Hiregoudar, Sumathi S.; Kilara, Nalini

Context: Acute myeloid leukemia (AML) is a heterogeneous disease. Approximately 80% of older AML patients will die of their disease or its treatment with currently available antileukemic therapy because of the adverse prognostic risk factors. In elderly patients who are not candidates for induction chemotherapy (IC) or who declines IC, the preferred induction regimen is with hypomethylating agents (HMAs). In India, data regarding therapy with HMA, response to therapy and overall survival (OS) is seldom reported. Aims: This study aims to study the response rate and survival of patients treated with HMAs in whom IC was not feasible. Settings and Design: This is retrospective and descriptive single-center study. Subjects and Methods: Data of newly diagnosed AML patients who were unfit for IC and treated with HMA in our institution was collected retrospectively and analyzed. Results: Twenty-three patients received HMAs as a treatment for AML. Eight (34.7%) of 23 patients had initial response to therapy (two [25%] had complete remission [CR], four [50%] had CR with incomplete hematologic recovery, one [12.5%] had partial remission) and one (12.5%) had stable disease. The median progression-free survival and OS observed are 6.06 ± 0.65 months and 7 ± 1.32 months, respectively.Conclusions: HMAs provide an important additional treatment option in newly diagnosed AML patients who are older, with poor performance status, higher comorbidity indices, and who refuse IC.

INDIA; ACUTE myeloid leukemia; OLDER patients; THERAPEUTICS; PROGRESSION-free survival

Indian Journal of Medical & Paediatric Oncology, 2020, Vol 41, Issue 2, p202

0971-5851

Academic Journal

10.4103/ijmpo.ijmpo_155_19